Cancer immunotherapies activate patients’ own immune systems to kill cancer cells. A common technique used in cancer immunotherapy uses soluble antibodies that bind to cancer cell specific antigens and induce an immune response against the cancer cells. However, a major limitation of antibody technologies is that they can only recognize antigens on the outside of the cell, and for some cancers, it is challenging or impossible to identify cancer-specific surface antigens. T-cell receptors (TCRs), which are normally embedded in T-cell membranes, bind to specific target antigens that arise from inside the cell. Soluble TCRs that act analogously to antibodies have therefore been proposed as a promising new immunotherapy strategy that could immensely increase the number of targetable antigens. Unfortunately, solubilizing TCRs remains extremely challenging and soluble TCRs are frequently unstable and suffer from low yields. This technology solves the stability issues associated with soluble TCRs, increases yield, and multimerizes the soluble TCRs to increase target affinity.